Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.02 USD | -6.96% | -13.40% | -11.01% |
May. 09 | Earnings Flash (INMB) INMUNE BIO Reports Q1 Revenue $14,000 | MT |
Apr. 30 | INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial | CI |
Business Summary
Number of employees: 14
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
INKmune and DN-TNF Product Platform
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -58.56% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -58.56% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Moss
FOU | Founder | 54 | 15-08-31 |
Mark Lowdell
FOU | Founder | 61 | 15-08-31 |
Raymond Tesi
CEO | Chief Executive Officer | 68 | 15-08-31 |
Tara Lehner
CTO | Chief Tech/Sci/R&D Officer | - | - |
General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Marcia Allen
BRD | Director/Board Member | 73 | 19-11-18 |
Raymond Tesi
CEO | Chief Executive Officer | 68 | 15-08-31 |
Scott Juda
BRD | Director/Board Member | 53 | 18-03-12 |
Director/Board Member | 64 | 19-08-07 | |
J. Ganjei
BRD | Director/Board Member | 50 | 16-08-31 |
David Moss
FOU | Founder | 54 | 15-08-31 |
Director/Board Member | 66 | 16-11-30 | |
Mark Lowdell
FOU | Founder | 61 | 15-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 19,760,985 | 13,398,158 ( 67.80 %) | 0 | 67.80 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.01% | 213M | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- INMB Stock
- Company INmune Bio, Inc.